Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Evofem Biosciences, Inc. (EVFM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AGREEMENT",
"FORM OF SENIOR SUBORDINATED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FI...",
"[FORM OF SERIES [A][B PREPAID] WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MA...",
"RECITALS"
09/27/2023 8-K Quarterly results
08/18/2023 8-K/A Quarterly results
08/14/2023 8-K Quarterly results
Docs: "Evofem Biosciences Announces Financial Results for the Second Quarter of 2023"
08/10/2023 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submiss...
Docs: "CERTIFICATE OF DESIGNATIONS OF SERIES E-1 CONVERTIBLE PREFERRED STOCK OF",
"RECITALS",
"RECITALS",
"FORM OF WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LO...",
"FORM OF SENIOR SUBORDINATED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FI...",
"____________ ____________ ____________"
07/17/2023 8-K Material Modifications to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Amendments to Articles o...
Docs: "ARTICLE I STOCKHOLDERS"
07/10/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "RECITALS",
"FORM OF SENIOR SUBORDINATED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FI...",
"FORM OF WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LO...",
"RECITALS"
06/16/2023 8-K Quarterly results
Docs: "Evofem Biosciences Announces Financial Results for the First Quarter of 2023"
06/01/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023"
05/17/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies that: FIRST: The name of this Corporation is Evofem Biosciences, Inc."
05/05/2023 8-K Other Events  Interactive Data
04/28/2023 8-K Quarterly results
Docs: "EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET DATA December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 2,769 $ 7,732 Restricted cash 1,207 5,056 Trade accounts receivable, net 1,126 6,449 Inventories 5,379 7,674 Prepaid and other current assets 2,218 3,229 Total current assets 12,699 30,140 Property and equipment, net 3,940 5,774 Operating lease right-of-use assets 4,406 5,395 Other noncurrent assets 4,118 1,203 Total assets $ 25,163 $ 42,512 Liabilities, convertible and redeemable preferred stock and stockholders’ deficit Current liabilities: Accounts payable $ 14,984 $ 10,316 Convertible notes payable - carried at fair value 39,416 81,717 Convertible notes payable - Adjuvant 26,268 27,209 Accrued expenses 4,124 8,370 Accrued compens..."
04/14/2023 8-K Quarterly results
03/24/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FORM OF SECURITIES PURCHASE AGREEMENT",
"FORM OF SENIOR SUBORDINATED CONVERTIBLE NOTE",
"FORM OF WARRANT",
"FORM OF REGISTRATION RIGHTS AGREEMENT"
03/20/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
03/14/2023 8-K Entry into a Material Definitive Agreement, Other Events  Interactive Data
Docs: "SECURITIES PURCHASE AGREEMENT",
"FORM OF SENIOR SUBORDINATED CONVERTIBLE NOTE",
"FORM OF WARRANT",
"REGISTRATION RIGHTS AGREEMENT"
03/10/2023 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
03/09/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Evofem Biosciences Appoints Interim Chief Financial Officer"
02/23/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES PURCHASE AGREEMENT",
"FORM OF SENIOR SUBORDINATED CONVERTIBLE NOTE",
"FORM OF WARRANT",
"FORM OF REGISTRATION RIGHTS AGREEMENT"
01/12/2023 8-K Other Events  Interactive Data
Docs: "Evofem’s Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor"
01/10/2023 8-K Other Events  Interactive Data
Docs: "Costco Adds Phexxi® to Member Prescription Program"
01/09/2023 8-K Quarterly results
12/30/2022 8-K Quarterly results
12/21/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
10/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/06/2022 8-K Quarterly results
10/05/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "T H E H O M E O F P H E X X I"
09/16/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "FORBEARANCE AGREEMENT",
"FORBEARANCE AGREEMENT",
"SUBORDINATION AGREEMENT",
"EXCHANGE AGREEMENT",
"EXCHANGE AGREEMENT",
"Evofem Biosciences, Inc. Right To Receive Common Stock",
"THIRD AMENDMENT TO SECURITIES PURCHASE AND SECURITY AGREEMENT",
"SECOND AMENDMENT TO SECURITIES PURCHASE AGREEMENT",
"Evofem Announces Successful Debt Restructuring"
08/10/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
08/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Evofem Biosciences Strengthens Board of Directors"
06/14/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy